PARP Inhibitors Market Size, Share & Trends Analysis Report By Product (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), Veliparib, Other Pipeline Drugs), By Indication, By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global PARP Inhibitors Market Snapshot

Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Clinical Trial/Pipeline Analysis

4.7. Industry Analysis – Porter’s Five Forces Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Technology Advancement in PARP Inhibitors

4.10. Key Trends in the Market

Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis

5.1. Product Type & Market Share, 2024 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

5.2.1. Niraparib (Zejula)

5.2.2. Olaparib (Lynparza)

5.2.3. Rucaparib (Rubraca)

5.2.4. Talazoparib (Talzenna)

5.2.5. Veliparib

5.2.6. Other Pipeline Drugs

Chapter 6. PARP Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis

6.1. Indication Analysis & Market Share, 2024 & 2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

6.2.1. Ovarian Cancer

6.2.2. Breast cancer

6.2.3. Prostate and Pancreatic Cancer

Chapter 7. PARP Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by product, 2021-2034

7.1.2. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by indication, 2021-2034

7.1.3. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

7.2. Europe

7.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034

7.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034

7.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034

7.3. Asia Pacific

7.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034

7.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034

7.3.3. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034

7.4. Latin America

7.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million)

7.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million)

7.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034

7.5. MEA

7.5.1. MEA revenue PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million) 2021-2034

7.5.2. MEA revenue PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million) 2021-2034

7.5.3. MEA revenue PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1 Johnson & Johnson Services, Inc.
8.2.2 Merck KGaA
8.2.3 GSK plc.
8.2.4 Pfizer Inc.
8.2.5 AbbVie Inc.
8.2.6 Teva Pharmaceutical Industries Ltd.
8.2.7 Artios Pharma
8.2.8 Genentech, Inc.
8.2.9 Karyopharm Therapeutics Inc.
8.2.10 Repare Therapeutics Inc
8.2.11 ONO PHARMACEUTICAL CO., LTD
8.2.12 Jiangsu Hengrui Pharma Co., Ltd.
8.2.13 Bristol-Myers Squibb Co
8.2.14 AstraZeneca plc
8.2.15 Checkpoint Therapeutics, Inc.
8.2.16 Eisai Co., Ltd.
8.2.17 IMPACT Therapeutics
8.2.18 JEIL PHARMA CO.,LTD.
8.2.19 Kyowa Kirin Co., Ltd
8.2.20 SyntheX

8.2.28. Other Prominent Players

Segmentation Of PARP Inhibitors Market

Global PARP Inhibitors Market by Product

• Niraparib (Zejula)
• Olaparib (Lynparza)
• Rucaparib (Rubraca)
• Talazoparib (Talzenna)
• Veliparib
• Other Pipeline Drugs

Global PARP Inhibitors Market by Indication

• Ovarian Cancer
• Breast cancer
• Prostate and Pancreatic Cancer

Global PARP Inhibitors Market Based on Region

• Europe PARP Inhibitors Market by Country
  • Germany
  • Poland
  • France
  • Italy
  • Spain
  • UK
  • Rest of Europe
• North America PARP Inhibitors Market by Country
  • U.S.
  • Canada
• Asia Pacific PARP Inhibitors Market by Country
  • India
  • China
  • Japan
  • Australia
  • Rest of Asia Pacific
• Latin America PARP Inhibitors Market by Country
  • Brazil
  • Rest of Latin America
• Middle East & Africa PARP Inhibitors Market by Country
  • South Africa
  • Rest of MEA

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

• Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
• External and internal proprietary databases, regulatory databases, and relevant patent analysis
• Statistical databases, National government documents, and market reports
• Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

• Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
• Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
• Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
• End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.